Premium
Synthesis, Characterisation and In Vitro Anticancer Activity of Hexanuclear Thiolato‐Bridged Arene Ruthenium Metalla‐Prisms
Author(s) -
Furrer Mona A.,
Garci Amine,
DenoyelleDiMuro Emmanuel,
Trouillas Patrick,
Giannini Federico,
Furrer Julien,
Clavel Catherine M.,
Dyson Paul J.,
SüssFink Georg,
Therrien Bruno
Publication year - 2013
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201203712
Subject(s) - ruthenium , trifluoromethanesulfonate , chemistry , in vitro , tris , cisplatin , cytotoxic t cell , stereochemistry , medicinal chemistry , biochemistry , medicine , chemotherapy , catalysis
Hexanuclear thiolato‐bridged arene ruthenium metalla‐prisms of the general formula [( p ‐cymene) 6 Ru 6 (SR) 6 (tpt) 2 ] 6+ (R=CH 2 Ph, CH 2 C 6 H 4 ‐ p ‐ t Bu, CH 2 CH 2 Ph; tpt=2,4,6‐tris(4‐pyridyl)‐1,3,5‐triazine), obtained from the dinuclear precursors [( p ‐cymene) 2 Ru 2 (SR) 2 Cl 2 ], AgCF 3 SO 3 and tpt, have been isolated and fully characterised as triflate salts. The metalla‐prisms are highly cytotoxic against human ovarian cancer cells, especially towards the cisplatin‐resistant cell line A2780cisR (IC 50 <0.25 μ M ).